New Delhi, March 20 Eris Lifesciences launched a generic version of Semaglutide under the brand name 'Sundae' in the country on Friday, capitalizing on the expiration of patents for molecules similar to Ozempic and Wegovy in India.The company stated that it is introducing the diabetes and...
New Delhi, March 3 NATCO Pharma announced on Tuesday the launch of generic Pomalidomide capsules in the US market, indicated for the treatment of adult patients with blood and bone marrow cancer, in partnership with Breckenridge Pharmaceutical, Inc.Pomalidomide capsule is a generic version of...
blood cancer
bone marrow cancer
breckenridge pharmaceutical
cancer treatment
drug development
fda approval
generic pharmaceuticals
hiv
kaposi sarcoma
multiple myeloma
natcopharmapharmaceutical products
pomalidomide
specialty pharmacies
us market
New Delhi, February 24 Eris Lifesciences announced on Tuesday that it has partnered with Natco Pharma for the commercialization of semaglutide in India.Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy for the management of Type 2 diabetes and chronic...
New Delhi, February 12 Natco Pharma announced on Thursday that its consolidated net profit increased by 14% year-on-year to Rs 151 crore for the third quarter ended December 31, 2025.The drug firm reported a net profit of Rs 132 crore for the October-December quarter of the previous fiscal...